InflaRx
Clinical-stage biopharmaceutical company developing inhibitors of the C5a–C5aR signaling axis for acute and chronic inflammatory diseases. Core activities include target discovery and preclinical translation, IND/CTA enabling GLP studies, antibody and small‑molecule lead optimisation, Phase I–III clinical development with adaptive designs, regulatory submissions and expedited-pathway interactions, coordination of third‑party manufacturing and technical transfers, pharmacovigilance and hospital-market commercialization planning.
Industries
Nr. of Employees
small (1-50)
Products
vilobelimab
Intravenous monoclonal antibody that inhibits C5a‑mediated biological activity; advanced clinical development for inflammatory and respiratory indications. Regulatory milestones include U.S. emergency use authorization and European Commission approval for a defined ARDS indication.
INF904
Orally administered low‑molecular‑weight antagonist of the C5a receptor developed for complement‑mediated inflammatory disorders; characterised in preclinical models and early clinical studies with topline Phase 2a data reported for dermatology indications.
IFX002
Preclinical next‑generation anti‑C5a antibody with modified humanization and altered pharmacokinetic properties intended for lifecycle management of the antibody program.
vilobelimab
Intravenous monoclonal antibody that inhibits C5a‑mediated biological activity; advanced clinical development for inflammatory and respiratory indications. Regulatory milestones include U.S. emergency use authorization and European Commission approval for a defined ARDS indication.
INF904
Orally administered low‑molecular‑weight antagonist of the C5a receptor developed for complement‑mediated inflammatory disorders; characterised in preclinical models and early clinical studies with topline Phase 2a data reported for dermatology indications.
IFX002
Preclinical next‑generation anti‑C5a antibody with modified humanization and altered pharmacokinetic properties intended for lifecycle management of the antibody program.
Expertise Areas
- Complement-targeted therapeutic discovery and development (C5a/C5aR)
- Monoclonal antibody therapeutics development
- Oral small‑molecule GPCR antagonist development
- Translational pharmacology and in vivo disease models
Key Technologies
- Monoclonal antibody therapeutics
- Small‑molecule GPCR antagonists
- Rodent and non‑human primate disease models
- GLP‑compliant toxicology studies
News & Updates
Webcast presenting topline Phase 2a data for the oral C5aR antagonist in hidradenitis suppurativa and chronic spontaneous urticaria.
Presentation of corporate and clinical updates at an investor and industry conference.
Corporate press release reporting topline Phase 2a data for the oral C5aR antagonist in hidradenitis suppurativa and chronic spontaneous urticaria.
Press release announcing initiation of a Phase III clinical program for the lead anti‑C5a monoclonal antibody in hidradenitis suppurativa.
Press release reporting positive Phase II IXCHANGE data for the lead antibody in ANCA‑associated vasculitis.
Press release announcing award of government grant (up to EUR 43.7 million) to support clinical development and certain manufacturing activities for the lead antibody program.
Webcast presenting topline Phase 2a data for the oral C5aR antagonist in hidradenitis suppurativa and chronic spontaneous urticaria.
Presentation of corporate and clinical updates at an investor and industry conference.
Corporate press release reporting topline Phase 2a data for the oral C5aR antagonist in hidradenitis suppurativa and chronic spontaneous urticaria.
Press release announcing initiation of a Phase III clinical program for the lead anti‑C5a monoclonal antibody in hidradenitis suppurativa.
Press release reporting positive Phase II IXCHANGE data for the lead antibody in ANCA‑associated vasculitis.
Press release announcing award of government grant (up to EUR 43.7 million) to support clinical development and certain manufacturing activities for the lead antibody program.